Hai Li Biology: It is expected that after the disclosure of the 2025 annual report, there may be a risk warning for delisting.

Haili Biology announced that the company expects to achieve operating income of 1.9 billion to 1.95 billion yuan in the year 2025, after deducting non-operating income unrelated to main business and income without commercial substance. The net profit attributable to the owners of the parent company after deducting non-recurring gains and losses will be negative. This will trigger a situation where the company's stock may be subject to delisting risk warning according to Rule 9.3.2 of the Shanghai Stock Exchange Listing Rules. The company's stock may be subject to delisting risk warning after the disclosure of the 2025 annual report.